Peptide EZH2 was already validated as a target for cancer immunotherapy (Steele et al, 2006).
However, since DZNep may affect other methyltransferases, we enrolled in our study also two molecules belonging to a new class of catalytic inhibitors, validated against a panel of histone methyltransferases [ 32, 40], MC1948, which has been already validate as EZH2 inhibitor in myoblasts [ 28] and a new, more effective, derivative, MC1945.
Its use as a measurement device, capable of generating geometric data in close-range environment has been already validated.
The model has been already validated in clinical trials.
As for osa-MIR164, the subset of the Arabidopsis NAC-domain transcription factor genes that include the CUP-SHAPED COTYLEDON (CUC1, CUC2 and CUC3) genes were already validate as targets [ 32].
With regard to the positive correlations between E-cadherin and hypoxia-related markers, we currently have no biologically plausible explanation for this finding, but would assume that it is unlikely that these findings are the result of technical shortcomings of our immunohistochemical protocols, as these were already validated extensively in prior studies (e.g., Mayer et al (2008)).
Interestingly, several well-known target genes including IRS1, IGFBP3, DNMT3A, HOXA9, TNF, etc. which are identified by our new screening approach, were already validated in wet lab experiments and reported as targets of multiple miRNAs (miR-145, miR-125b, miR-126 and miR-29) [ 69- 73].
The prediction was already validated in a Fe0/sand system using methylene blue as an operational tracer.
